
ADVM
Adverum Biotechnologies Inc.
$3.08
+$0.05(+1.65%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$66.31M
Volume
65.63K
52W Range
$1.78 - $8.56
Target Price
$19.75
Order:
Income Statement
Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
Total Revenue | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
Total Revenue | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
COST OF GOODS SOLD | ||||||||||||
Cost of Revenue | $-100.0K | $-600.0K | $-500.0K | $-100.0K | -- | -- | -- | -- | -- | -- | ||
GROSS PROFIT | ||||||||||||
Gross Profit | $2.3M | $1.5M | $1.8M | $1.6M | $250.0K | -- | $7.5M | -- | $3.6M | $1.0M | ||
OPERATING EXPENSES | ||||||||||||
Operating Expenses | $-50.1M | $-116.7M | $-60.7M | $-79.7M | $-68.8M | $118.0M | $153.6M | $157.1M | $132.5M | $140.2M | ||
Research & Development | $25.5M | $31.7M | $39.8M | $50.1M | $40.4M | $73.3M | $89.2M | $99.3M | $77.5M | $77.0M | ||
Research Expense | $25.5M | $31.7M | $39.8M | $50.1M | $40.4M | $73.3M | $89.2M | $99.3M | $77.5M | $77.0M | ||
Selling, General & Administrative | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
General & Administrative Expenses | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
Salaries & Wages | $-11.5M | $-11.4M | $-8.7M | $-13.4M | $-9.9M | $300.0K | $1.6M | -- | -- | -- | ||
Depreciation & Amortization | $-812.0K | $-1.6M | $-2.1M | $-1.8M | $-1.6M | $4.2M | -- | -- | -- | -- | ||
Depreciation & Amortization | $-812.0K | $-1.6M | $-2.1M | $-1.8M | $-1.6M | $4.2M | -- | -- | -- | -- | ||
Other Operating Expenses | $-50.1M | $-116.7M | $-60.7M | $-4.1M | $-995.0K | $-5.1M | $-2.6M | $-2.5M | -- | -- | ||
OPERATING INCOME | ||||||||||||
Operating income | $-45.3M | $-54.6M | $-58.8M | $-73.1M | $-68.5M | $-118.0M | $-146.1M | $-157.1M | $-128.9M | $-139.2M | ||
EBITDA | $-45.9M | $-112.9M | $-53.5M | $-72.1M | $-64.2M | $-113.8M | $-141.5M | $-150.6M | $-99.3M | $-119.8M | ||
NON-OPERATING ITEMS | ||||||||||||
Intinc | -- | -- | -- | $4.2M | $4.1M | -- | -- | -- | -- | -- | ||
Net Non-Operating Interest Income/Expense | -- | -- | -- | $4.2M | $4.1M | -- | -- | -- | -- | -- | ||
Gain on Sale of Securities | $-6.0K | $6.0K | $-182.0K | $168.0K | $33.0K | -- | -- | -- | -- | -- | ||
Other Income/Expense | $-364.0K | $-768.0K | $-2.5M | $-168.0K | $-33.0K | $-1.6M | $-154.0K | $2.7M | $-6.8M | $-8.3M | ||
Other Special Charges | $370.0K | $762.0K | $2.7M | $4.2M | -- | $1.6M | $582.0K | $2.7M | $5.7M | $8.2M | ||
SPECIAL ITEMS | ||||||||||||
Restructring And Mn A Income | $2.6M | -- | -- | -- | -- | -- | -- | $4.7M | -- | -- | ||
Special Income Charges | $-2.6M | $-60.7M | -- | $-5.0M | -- | -- | $-1.1M | $-6.8M | $-224.0K | -- | ||
Impairment of Capital Assets | -- | $60.7M | -- | $5.0M | -- | -- | $1.1M | $2.1M | -- | -- | ||
PRE-TAX INCOME | ||||||||||||
EBIT | $-47.5M | $-114.5M | $-56.1M | $-73.9M | $-64.5M | $-118.0M | $-146.1M | $-157.1M | $-123.2M | $-130.9M | ||
Pre-Tax Income | $-47.5M | $-114.5M | $-56.1M | $-73.9M | $-64.5M | $-116.4M | $-145.5M | $-154.5M | $-123.2M | $-130.9M | ||
INCOME TAX | ||||||||||||
Tax Provision | -- | $-775.0K | $-10.2M | $-1.3M | $-298.0K | $1.1M | $-7.0K | $74.0K | $-1.1M | -- | ||
NET INCOME | ||||||||||||
Net Income | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
Net Income (Continuing Operations) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
Net Income (Discontinued Operations) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
Net Income (Common Stockholders) | $-47.5M | $-113.7M | $-56.3M | $-72.5M | $-64.5M | $-117.5M | $-145.5M | $-154.5M | $-122.1M | $-130.9M | ||
TOTALS | ||||||||||||
Total Expenses | $-50.2M | $-117.3M | $-61.2M | $79.7M | $-68.8M | $118.0M | $153.6M | $157.1M | $132.5M | $140.2M | ||
SHARE & EPS DATA | ||||||||||||
Average Shares Outstanding | $25.5M | $36.2M | $43.7M | $61.4M | $64.1M | $85.1M | $98.0M | $9.9M | $10.1M | $19.8M | ||
Average Shares Outstanding (Diluted) | $25.5M | $36.2M | $43.7M | $61.4M | $63.8M | $85.1M | $98.0M | $9.9M | $10.1M | $19.8M | ||
Shares Outstanding | $26.9M | $42.1M | $62.2M | $63.2M | $79.7M | $9.8M | $9.9M | $10.1M | $20.8M | $20.9M | ||
Basic EPS | -- | -- | -- | -- | -- | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
Diluted EPS | $-1.86 | $-3.14 | $-1.29 | $-1.18 | $-1.01 | $-1.38 | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.48 | $-15.6 | $-11.6 | $-6.62 | ||
OTHER METRICS | ||||||||||||
Other Gand A | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | $44.6M | $64.4M | $57.9M | $55.1M | $63.1M | ||
Other Impairment Of Capital Assets | -- | $-11.2M | -- | -- | -- | -- | $800.0K | -- | -- | -- | ||
Rent And Landing Fees | $22.1M | $24.4M | $20.9M | $24.6M | $28.4M | -- | -- | -- | -- | -- | ||
Restruct | $2.6M | -- | -- | -- | -- | -- | -- | $4.7M | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | ADVM | $3.08 | +1.7% | 65.63K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Adverum Biotechnologies Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW